All Stories

  1. Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn’s and Colitis (PREdiCCt) prospective cohort study
  2. Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use
  3. Delivering a Modified Mindfulness Based Stress Reduction Intervention for Inflammatory Bowel Disease in Adolescents and Young Adults: Assessing Feasibility, Acceptability, and Effectiveness
  4. Zenker peroral endoscopic myotomy (Z-POEM) is safe and effective for the management of pharyngeal pouch: a multicentre retrospective cohort study
  5. P170 Zenker peroral endoscopic myotomy (Z-POEM) is a safe and feasible alternative first-line treatment for zenker’s diverticulum
  6. Endoscopic Suturing for Defect Closure in the Upper Gastrointestinal Tract: A Retrospective Cohort Study
  7. Targeted screening of at-risk patients with chronic heartburn using a non-endoscopic capsule sponge device can enhance the detection of Barrett’s oesophagus
  8. Systemic sclerosis–related fecal incontinence: a scoping review focusing on a neglected manifestation
  9. A multimodal endoscopic approach for esophageal fistula closure
  10. The A to Z of Peroral Endoscopic Myotomy
  11. The safety and efficacy of endoscopic approaches for the management of Zenker’s diverticulum: a multicentre retrospective study
  12. A disease-associated gene desert directs macrophage inflammation through ETS2
  13. Endoscopic suturing and clipping devices for defects in the GI tract
  14. P172 A comparison of the safety and efficacy of flexible versus rigid endoscopic approaches for the management of zenker’s diverticulum
  15. P223 Evaluation of the safety and efficacy of transoral incisionless fundoplication (TIF2.0) for gastro-oesophageal reflux disease: a UK cohort study
  16. P262 Performance of endoscopic approaches for the treatment of Zenker’s diverticulum: a systematic review and meta-analysis
  17. P272 Safety and efficacy of cryoablation for the treatment of Barrett’s oesophagus: a systematic review and meta-analysis
  18. P152 Safety and efficacy of endoscopic vacuum therapy for the management of leaks following bariatric surgery: a systematic review and meta-analysis
  19. P221 Zenker per-oral endoscopic myotomy (Z-POEM) is safe and effective for the management of pharyngeal pouch
  20. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
  21. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
  22. Role of oesophageal balloon cryoablation in combination with personalised immunotherapy to achieve luminal control in metastatic oesophageal cancer: a case report
  23. The endoscopic management of oesophageal strictures
  24. Metabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?
  25. Peroral endoscopic myotomy for the management of symptomatic cricopharyngeal bar (C-POEM): a case series and video demonstration
  26. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
  27. Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients
  28. Symptomatic duodenal metastasis from a small cell lung cancer primary: a rare case
  29. Metabolic and Bariatric Endoscopy: A Mini-Review
  30. Management of a large percutaneous endoscopic gastrostomy tube-associated gastric ulcer with endoscopic suturing
  31. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
  32. Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease
  33. A disease-associated gene desert orchestrates macrophage inflammatory responses via ETS2
  34. Phenome-Wide Association Study of Drugs and Co-morbidities Associated with Gastrointestinal Dysfunction in Systemic Sclerosis
  35. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
  36. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a pr...
  37. Between progress and changing times: The journey of UEG Education Committee's chair
  38. Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID ‐19 pandemic: the PREPARE‐IBD multicentre cohort study
  39. Blood and guts
  40. Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease
  41. Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn’s Disease: Experience from the METRIC Trial
  42. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
  43. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
  44. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients
  45. The Relationship Between Mucosal Microbiota, Colitis, and Systemic Inflammation in Chronic Granulomatous Disorder
  46. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
  47. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
  48. PMO-29 Switching between infliximab biosimilars: experience from two inflammatory bowel disease centres
  49. Benefits of Structured Pediatric to Adult Transition in Inflammatory Bowel Disease
  50. Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients
  51. The relationship between mucosal microbiota, colitis and systemic inflammation in Chronic Granulomatous Disorder
  52. Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis
  53. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
  54. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
  55. Endoscopy during the peak of COVID-19 pandemic: impact on activity and financial implications for a tertiary referral center in London
  56. Editorial: fatigue—difficult to assess and difficult to treat
  57. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
  58. UEG Guidelines framework to guide clinical practice
  59. Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic
  60. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
  61. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
  62. The cost-effectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy
  63. UEG Education—building on success
  64. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
  65. Diagnosis and management of bile acid diarrhoea: a survey of UK expert opinion and practice
  66. Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn’s disease patients: the METRIC diagnostic accuracy study
  67. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn’s and Colitis
  68. Chronic Granulomatous Disorder–Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level
  69. Editorial: combination immunosuppressive therapy to treat Crohn’s disease - ready for all age groups?
  70. Radiological findings in gastrointestinal scleroderma
  71. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
  72. Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis
  73. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
  74. Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia
  75. In memory of Dr Tomer Adar
  76. A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population
  77. Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease
  78. Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn’s disease: patient acceptability and perceived burden
  79. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial
  80. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis
  81. Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine
  82. There is a need for new systemic sclerosis subset criteria. A content analytic approach
  83. PTH-041 Definitive management of a very rare cause of significant acute upper gastrointestinal bleeding: gastric lipoma resected by hybrid endoscopic submucosal dissection
  84. PTH-054 Endoscopic submucosal dissection (esd) of gastric and rectal neuroendocrine tumours (nets): a case series from a tertiary referral centre (with video)
  85. AODTU-001 Radiofrequency ablation in patients with symptomatic anaemia secondary to gastric antral vascular ectasia
  86. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care
  87. Small bowel obstruction caused by a migrated Obalon gastric bariatric balloon: nonsurgical management by antegrade double-balloon panenteroscopy
  88. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial
  89. The role of dietary supplements in inflammatory bowel disease
  90. Small and Large Intestinal Involvement and Nutritional Issues
  91. Gallstone mimicry: a rare cause of abdominal pain
  92. Gastrointestinal manifestations of systemic sclerosis
  93. The ABC of E-learning: Utilizing E-learning resources for training and research in gastroenterology
  94. Elevated liver enzymes in inflammatory bowel disease
  95. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis
  96. P.14.3 CORRELATION BETWEEN CLINICAL RESPONSE AND ANEMIA RESOLUTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNF INHIBITORS
  97. Endoscopic resection of a giant ileal inflammatory fibroid polyp by retrograde double-balloon enteroscopy
  98. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease
  99. Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs
  100. OP-16 DIETARY INTERVENTION USING THE LOW FODMAP DIET VERSUS THE “MILK, EGG, WHEAT AND SOYA FREE” DIET FOR TREATMENT OF FUNCTIONAL GUT DISORDERS A SINGLE CENTRE EXPERIENCE
  101. Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptoms
  102. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis
  103. Intractable diarrhoea despite immune reconstitution in an HIV positive man
  104. UEG E‐learning: The future has arrived
  105. Indurated plaques on the penis
  106. Gut symptoms in diabetics correlate with components of the rectoanal inhibitory reflex, but not with pudendal nerve motor latencies or systemic autonomic neuropathy
  107. PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis
  108. Hepatic portal venous gas and portal venous thrombosis following colonoscopy in a patient with terminal ileal Crohn's disease
  109. Irritable bowel syndrome
  110. Travel health and pretravel preparation in the patient with inflammatory bowel disease
  111. Sa1264 A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centred Pilot Study to Assess the Symptomatic Treatment of Ulcerative Colitis With Cannabidiol
  112. A rare cause of abdominal pain, diarrhoea and GI bleeding
  113. UEG Education: time to shape the future
  114. METRIC (MREnterography or ulTRasound in Crohn’s disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in tho...
  115. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis
  116. OC-055 Ibd Passport-developing An Evidence-based Internet Travel Resource For Inflammatory Bowel Disease: A Report Of The Initial Stages Of Implementation
  117. PTU-092 Patient And Professionals Perceptions Of Travel Behaviour In Inflammatory Bowel Disease
  118. PWE-115 Patients Continue To Travel Abroad Despite Recently Active Disease And Travel Concerns: Results Of A Single Centre Study In Inflammatory Bowel Disease And Travel
  119. PWE-183 Preliminary Significant Findings From A Randomised Control Trial Of Posterior Tibial Nerve Stimulation In Systemic Sclerosis Associated Faecal Incontinence
  120. P574 A recent flare of disease does not prohibit travel: early results of a single centre study in inflammatory bowel disease and travel
  121. P553 A single-centre pilot study examining internet use for health related information among patients with inflammatory bowel disease
  122. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management
  123. Using an ‘action set’ for the management of acute upper gastrointestinal bleeding
  124. Bloody Diarrhoea
  125. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy
  126. PTH-132 Iron Deficiency Anaemia Nurse Led Clinic: Audit of 1st Year
  127. P57 Comparative Cost-Effectiveness of IGRA to Detect Latent TB Infection in UK Inflammatory Bowel Disease Patients Initiating Anti-TNFα Agents: Abstract P57 Table 1
  128. Weight loss and lumbosacral back pain in a 79-year-old Indian man
  129. Malignant mimicry—a 17-year-old with abdominal pain and weight loss
  130. PTU-113 Quality of life in patients with ileoanal pouch: a survey comparing two different patient populations
  131. PTU-096 The use of commercial interferon-γ release assays to screen for mycobacterial infection in inflammatory bowel disease patients initiating anti-TNF agents
  132. Irritable bowel syndrome
  133. Influence of smoking and other environmental factors in inflammatory bowel disease activity: what do our patients think?
  134. Iron deficiency anaemia is common in patients with an ileoanal pouch and is not always associated with inflammation
  135. There will be blood... a complete audit cycle
  136. Images of the terminal ileum are more convincing than cecal images for verifying the extent of colonoscopy
  137. Attitudes and Experiences of Adolescents in an Innovative IBD Transition Service
  138. Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome
  139. The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion
  140. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease
  141. Gastrointestinal Manifestations of Systemic Sclerosis
  142. Pharmacological modulation of gut mucosal and large vessel blood flow
  143. Reaping value from intellectual property: DuPont's strategic approach achieves global growth
  144. Ghrelin augments afferent response to distension in rat isolated jejunum
  145. The effect of different macronutrient infusions on appetite, ghrelin and peptide YY in parenterally fed patients
  146. Diabetes and the Gastrointestinal System
  147. Prokineticin-2, motilin, ghrelin and metoclopramide: Prokinetic utility in mouse stomach and colon
  148. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study
  149. Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome
  150. Sporadic duodenal adenoma is associated with colorectal neoplasia
  151. Ghrelin for the gastroenterologist: history and potential
  152. Biofeedback, not laxatives, improves symptoms, transit and autonomic tone in functional constipation
  153. Medical management of diverticular disease
  154. Colonic Disorders